MA28909B1 - Quinazolines utiles en tant que modulateurs de canaux ioniques - Google Patents

Quinazolines utiles en tant que modulateurs de canaux ioniques

Info

Publication number
MA28909B1
MA28909B1 MA29735A MA29735A MA28909B1 MA 28909 B1 MA28909 B1 MA 28909B1 MA 29735 A MA29735 A MA 29735A MA 29735 A MA29735 A MA 29735A MA 28909 B1 MA28909 B1 MA 28909B1
Authority
MA
Morocco
Prior art keywords
modulators
ionic channels
useful
quinazolines useful
quinazolines
Prior art date
Application number
MA29735A
Other languages
English (en)
Inventor
Dean M Wilson
Andreas P Termin
Jesus E Gonzalez Iii
Lev T D Fanning
Timothy D Neubert
Paul Krenitsky
Pramod Joshi
Dennis J Hurley
Urvi Sheth
Joshua S Boger
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA28909B1 publication Critical patent/MA28909B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
MA29735A 2004-09-02 2007-03-02 Quinazolines utiles en tant que modulateurs de canaux ioniques MA28909B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60724504P 2004-09-02 2004-09-02
US60703704P 2004-09-02 2004-09-02
US60703604P 2004-09-02 2004-09-02
US60715004P 2004-09-02 2004-09-02
US60703304P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
MA28909B1 true MA28909B1 (fr) 2007-10-01

Family

ID=35517001

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29735A MA28909B1 (fr) 2004-09-02 2007-03-02 Quinazolines utiles en tant que modulateurs de canaux ioniques

Country Status (18)

Country Link
EP (1) EP1784393B1 (fr)
JP (1) JP5014994B2 (fr)
KR (1) KR20070057914A (fr)
CN (1) CN101068794B (fr)
AT (1) ATE435214T1 (fr)
AU (1) AU2005282761B2 (fr)
BR (1) BRPI0514893A (fr)
CA (1) CA2578739A1 (fr)
DE (1) DE602005015231D1 (fr)
ES (1) ES2327945T4 (fr)
IL (1) IL181700A0 (fr)
MA (1) MA28909B1 (fr)
MX (1) MX2007002582A (fr)
NO (1) NO20071742L (fr)
NZ (1) NZ589252A (fr)
RU (1) RU2440991C2 (fr)
WO (1) WO2006028904A1 (fr)
ZA (1) ZA200702375B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
KR20080073749A (ko) * 2005-11-14 2008-08-11 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널 조절제로서 유용한 퀴나졸린
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
EP2043654A2 (fr) 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
WO2008069976A2 (fr) 2006-12-01 2008-06-12 President And Fellows Of Harvard College Composés et procédés pour imagerie et thérapie de tumeurs médiées par des enzymes
WO2008147864A2 (fr) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Procédés d'utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium
WO2008157500A1 (fr) * 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
EP2640366A2 (fr) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication
ES2610556T3 (es) 2011-01-31 2017-04-28 Council Of Scientific & Industrial Research 1-(4-metilfenilmetil)-5-oxo-{N-[(3-t-butoxicarbonil-aminometil)]-piperidin-1-il}-pirrolidin-2-carboxamidas quirales como inhibidores de la activación y adhesión de plaquetas inducidas por colágeno
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
CN109153652B (zh) * 2016-04-01 2021-07-27 上海瑛派药业有限公司 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
WO2019183589A1 (fr) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulateurs du facteur 2 d'initiation eucaryote
WO2020017569A1 (fr) * 2018-07-17 2020-01-23 日本ケミファ株式会社 Inhibiteur du canal calcique de type t
EP3924341A4 (fr) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Composés, compositions et procédés
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
WO2021069339A1 (fr) * 2019-10-10 2021-04-15 Esteve Pharmaceuticals, S.A. Dérivés d'homopipérazinyle et d'homopipéridinyle quinazolin-4(3h)-one possédant une activité plurimodale contre la douleur
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CN119757730A (zh) * 2024-12-24 2025-04-04 浙江省海洋水产研究所 一种河豚毒素的胶体金检测卡

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083144A (ja) * 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SV2002000205A (es) * 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
SE0004054D0 (sv) * 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0004055D0 (sv) * 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
EP1663994B1 (fr) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Composes de tetrahydroquinazoline utilises comme inhibiteurs de canaux ioniques potentiel-dependants
EP1891039A1 (fr) * 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Derives de quinoline utiles en tant que modulateurs de canaux ioniques

Also Published As

Publication number Publication date
HK1104544A1 (en) 2008-01-18
RU2440991C2 (ru) 2012-01-27
ZA200702375B (en) 2009-03-25
ES2327945T3 (es) 2009-11-05
NO20071742L (no) 2007-04-02
DE602005015231D1 (de) 2009-08-13
JP2008511670A (ja) 2008-04-17
NZ589252A (en) 2012-06-29
CN101068794B (zh) 2012-12-19
CN101068794A (zh) 2007-11-07
WO2006028904A1 (fr) 2006-03-16
JP5014994B2 (ja) 2012-08-29
ATE435214T1 (de) 2009-07-15
AU2005282761B2 (en) 2012-02-02
AU2005282761A1 (en) 2006-03-16
KR20070057914A (ko) 2007-06-07
MX2007002582A (es) 2008-01-14
IL181700A0 (en) 2007-07-04
BRPI0514893A (pt) 2007-11-27
RU2007111897A (ru) 2008-10-10
CA2578739A1 (fr) 2006-03-16
EP1784393B1 (fr) 2009-07-01
EP1784393A1 (fr) 2007-05-16
WO2006028904A9 (fr) 2006-06-22
ES2327945T4 (es) 2010-07-02

Similar Documents

Publication Publication Date Title
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
TW200519094A (en) Pyrimidines useful as modulators of voltage-gated ion channels
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20092637L (no) Fremgangsmater for behandling
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
EP2513343A4 (fr) Procédés et compositions pour traiter l'inflammation de la peau
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
NO20071272L (no) Modulatorer av muskarine reseptorer.
ATE540036T1 (de) Heterocyclische derivate als ionenkanalmodulatoren
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
WO2007058989A3 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques potentio-dependants
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE531703T1 (de) Benzochromenderivate